Local Head-Injury Patients Sought For Study Investigating Potential Treatment For Daytime Sleepiness
Local patients are being sought for a national clinical research study currently investigating a study medication for people who have had a head injury, concussion or bump on the head and feel sleepy or tired during the day. According to the Centers for Disease Control and Prevention, head injury is one of the most common neurologic disorders, affecting around 1.5 million Americans every year. Many people with a past head injury feel sleepy during the day, yet few people know that their sleepiness might be connected to this injury. "Currently, there are no treatments for patients who suffer from sleepiness during the day as a result of head injury, " according to study investigator Dr.
Wives of soldiers deployed to Iraq and Afghanistan are more likely to be diagnosed with depression, anxiety, sleep disorders and other mental health conditions than women whose husbands are not deployed, according to a new study by researchers at the University of North Carolina at Chapel Hill and the Uniformed Services University of the Health Sciences. The study, published Jan. 14, 2010, in The New England Journal of Medicine, examined medical records of the wives of active duty U.S. Army personnel, comparing those whose husbands were serving abroad with those whose husbands were not deployed. "This study confirms what many people have long suspected, " said Alyssa Mansfield, Ph.
VIVUS, Inc. (Nasdaq: VVUS) announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa® , an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication. The study announced demonstrated statistically significant improvement in the apnea/hypopnea index ("AHI" - a measure of the severity of sleep apnea) in patients with OSA treated with Qnexa for 28 weeks. Qnexa-treated patients also experienced significant weight loss, improvements in blood pressure, and overnight blood oxygen levels.
Only about 8 percent of high school students get enough sleep on an average school night, a large new study finds. The others are living with borderline-to-serious sleep deficits that could lead to daytime drowsiness, depression, headaches and poor performance at school. The study, which appears online in the Journal of Adolescent Health, evaluated responses from 12, 000 students in grades 9 through 12 who participated in the 2007 national Youth Risk Behavior Survey. The authors found that 10 percent of adolescents sleep only five hours and 23 percent sleep only six hours on an average school night. More females than males have sleep deficits as do more African-Americans and whites compared to Hispanics.
Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia
Actelion Ltd (SIX: ATLN) announced today that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared to placebo on objective and subjective wake after sleep onset (WASO). The finding was highly significant (p<0.001). In addition, several secondary endpoints of the study were met with statistical significance. In RESTORA 1, the use of almorexant was well-tolerated. However, in this study as well as in the ongoing non-pivotal program, certain safety observations were made that will require further evaluation and assessment in longer-term Phase III studies.
Research published in the current issue of the journal, Clinical Science, appears to have found a link between obstructive sleep apnoea and non-alcoholic steatohepatitis. Dr Anne-Christine Piguet and colleagues from the University of Bern, Switzerland, kept mice for a week in low-oxygen atmospheres and found that it led to increased levels of fat and inflammation in their livers. Apnoea means "without breath" and occurs when the muscles in the airways behind the tongue relax in sleep, causing the person to snore and briefly, to stop breathing. Nonalcoholic steatohepatitis (NASH) is a common, often "silent" liver disease occurring in around 40% of the population.